Baycrest

2. EXPLORING PROMISING DEMENTIA TREATMENTS Promising options have emerged to treat the brain. The majority of therapies have only shown benefits to mice, but some may work on patients, says Dr. Chertkow. These might also be more effective when administered in combination and doing so will provide researchers the opportunity to learn even more about the brain, he adds. Baycrest will continue to lead the way in this research by becoming the headquarters and research network centre for the Canadian Consortium on Neurodegeneration in Aging (CCNA). This ambitious initiative, led by the CCNA's scientific director, Dr. Chertkow, brings together 400 leading researchers across the country to develop a better understanding of neurodegenerative disorders, innovative treatments, effective prevention strategies and new diagnostic approaches to benefit people with dementia today. "I dream of Canada and Canadian scientists – working through the CCNA – delivering the breakthrough treatments for Alzheimer disease as we did long ago for diabetes," says Dr. Chertkow. "If we can deliver on our goals, then we will have made great progress in curing and preventing dementia." As well, individuals at the Kimel Family Centre for Brain Health and Wellness who have been identified as having a higher risk of developing dementia will qualify to participate in trials for combination therapy through Baycrest's Clinical Trials Unit, which will continue to provide access to groundbreaking drug and non-drug interventions. 3. BRINGING TOGETHER RESEARCH ACROSS THE SPECTRUM To reach a point where we can start to effectively diagnose, treat and prevent dementia, various types of research needs to come together. This includes work on the basic science of the human brain, clinical studies to improve care at the bedside, and innovative ideas to develop the latest technological tools that will transform the aging experience. Baycrest has designed its campus to advance the latest dementia research, care and innovative solutions. It is a recognized leader in exceptional residential care including long-term care, a retirement home, a hospital, a world renowned research centre, an innovation accelerator and a centre for education. "Scientists, clinicians and point-of-care staff work side-by-side, and are united through their vision of a world where every older adult enjoys a life of purpose, inspiration and fulfilment," says Dr. Allison Sekuler, Vice- President, Research and the Sandra A. Rotman Chair in Cognitive Neuroscience at Baycrest. "This collaborative approach empowers everyone on campus to contribute to confronting dementia." To find out more, visit baycrest.org/research. BrainMatters FALL/WINTER 2018 13 access to groundbreaking drug and non-drug Dr. Allison Sekuler

• Cover